Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.

ABSTRACT:

Importance

Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.

Objective

To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.

Design, setting, and participants

This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.

Exposures

The primary e

SUBMITTER: Lahteenvuo M 

PROVIDER: S-EPMC11561716 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature